Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Non-Current Deferred Tax Liability: 2010-2022

Historic Non-Current Deferred Tax Liability for Anika Therapeutics (ANIK) over the last 13 years, with Dec 2022 value amounting to $6.4 million.

  • Anika Therapeutics' Non-Current Deferred Tax Liability fell 71.25% to $2.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was $2.0 million, marking a year-over-year decrease of 71.25%. This contributed to the annual value of $6.4 million for FY2022, which is 36.63% down from last year.
  • Anika Therapeutics' Non-Current Deferred Tax Liability amounted to $6.4 million in FY2022, which was down 36.63% from $10.2 million recorded in FY2021.
  • In the past 5 years, Anika Therapeutics' Non-Current Deferred Tax Liability ranged from a high of $11.9 million in FY2020 and a low of $4.3 million during FY2019.
  • For the 3-year period, Anika Therapeutics' Non-Current Deferred Tax Liability averaged around $9.5 million, with its median value being $10.2 million (2021).
  • As far as peak fluctuations go, Anika Therapeutics' Non-Current Deferred Tax Liability tumbled by 59.72% in 2019, and later spiked by 174.65% in 2020.
  • Over the past 5 years, Anika Therapeutics' Non-Current Deferred Tax Liability (Yearly) stood at $10.8 million in 2018, then plummeted by 59.72% to $4.3 million in 2019, then surged by 174.65% to $11.9 million in 2020, then declined by 14.61% to $10.2 million in 2021, then crashed by 36.63% to $6.4 million in 2022.